Unlock instant, AI-driven research and patent intelligence for your innovation.

Uses of il-23 agonists and antagonists; related reagents

a technology of il-23 and cytokine, which is applied in the field of identification of mammalian cytokinelike proteins, can solve the problems of toxic side effects and ineffective present methods of treating cancer, and achieve the effect of inhibiting or preventing tumor growth

Inactive Publication Date: 2008-03-06
SCHERING CORP
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is based on the discovery that an agonist or antagonist of IL-23 can modulate tumor growth. The invention provides methods for using IL-23 agonists or antagonists to inhibit tumor growth, treat cancer or tumors, and diagnose them using specific binding compositions. The technical effects of the invention include the development of new methods for treating and diagnosing cancer or tumors, as well as new targets for cancer treatment."

Problems solved by technology

Immune response can produce pathological consequences, e.g., when it involves excessive inflammation, as in the autoimmune disorders, whereas impaired immune response may result in cancer.
Present methods for treating cancer are not completely effective, and cytokines, such as IL-12 or IFNgamma produce toxic side effects (see, e.g., Naylor and Hadden (2003) Int. Immunopharmacol. 3:1205-1215; Fernandez, et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples

I. General Methods

[0075] Standard methods in molecular biology are described (Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Sambrook and Russell (2001) Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Wu (1993) Recombinant DNA, Vol. 217, Academic Press, San Diego, Calif.). Standard methods also appear in Ausbel, et al. (2001) Current Protocols in Molecular Biology, Vols. 1-4, John Wiley and Sons, Inc. New York, N.Y., which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4).

[0076] Methods for protein purification including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization are described (Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 1, John Wiley and Sons, Inc., New...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.

Description

[0001] This application is a continuation of co-pending U.S. patent application Ser. No. 10 / 797,157, filed Mar. 9, 2004, which claims benefit from U.S. Provisional Patent Application No. 60 / 453,672, filed Mar. 10, 2003, each of which is incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention concerns uses of mammalian cytokine molecules and related reagents. More specifically, the invention relates to identification of mammalian cytokine-like proteins and inhibitors thereof that can be used in the treatment of proliferative disorders. BACKGROUND OF THE INVENTION [0003] Cancers and tumors can be controlled or eradicated by the immune system. The immune system includes several types of lymphoid and myeloid cells, e.g., monocytes, macrophages, dendritic cells (DCs), eosinophils, T cells, B cells, and neutrophils. These lymphoid and myeloid cells produce secreted signaling proteins known as cytokines. The cytokines include, e.g., interleukin-10 (IL-10), inte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00C12N5/00A61K38/00A61K39/00C07K14/54C07K14/715C07K16/24
CPCA61K38/00A61K39/00C07K16/244C07K14/54C07K14/7155A61K2039/505A61P1/14A61P29/00A61P35/00A61P35/02A61P37/02A61P43/00A61P9/14
Inventor OFT, MARTINMCCLANAHAN, TERRILL K.
Owner SCHERING CORP